Background: Moderate to severe asthma could be induced by diverse proinflammatory
cytokines, as IL-17 and IFN-γ, which are also related to treatment resistance and airway hyperresponsiveness.
Oxazolidines emerged as a novel approach for asthma treatment, since some chemical peculiarities
were suggested by previous studies.
Objective: The present study aimed to evaluate the IL-17A and IFN-γ modulatory effect of two new
oxazolidine derivatives (LPSF/NB-12 and -13) on mononucleated cells of patients with moderate and
Methods: The study first looked at potential targets for oxazolidine derivatives using SWISS-ADME.
After the synthesis of the compounds, cytotoxicity and cytokine levels were analyzed.
Results: We demonstrated that LPSF/NB-12 and -13 reduced IFN-γ and IL-17 production in peripheral
blood mononucleated cells from asthmatic patients in a concentrated manner. Our in silico analysis
showed the neurokinin-1 receptor as a common target for both compounds, which is responsible
for diverse proinflammatory effects of moderate and severe asthma.
Conclusion: The work demonstrated a novel approach against asthma, which deserves further studies
of its mechanisms of action.